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Abstract 
Background: Inflammation, coagulation, and cell stress contribute to atherosclerosis and its 
adverse events. A biomarker risk score (BRS) based on the circulating levels of biomarkers C-
reactive protein (CRP), fibrin degradation products (FDP), and heat shock protein-70 (HSP-70) 
representing these three pathways was a strong predictor of future outcomes. We investigated 
whether soluble urokinase activator receptor (suPAR), a marker of immune activation, is 
predictive of outcomes independent of the aforementioned markers, and whether its addition 
to a 3-BRS improves risk reclassification.  
Methods: CRP, FDP, HSP-70 and suPAR were measured in 3278 patients undergoing coronary 
angiography. The BRS was calculated by counting the number of biomarkers above a cutoff 
determined using the Youden’s index. Survival analyses were performed using models adjusted 
for traditional risk factors.  
Results: A high suPAR level ≥3.5 ng/ml was associated with all-cause death and MI (HR 1.83 
95%CI [1.43-2.35]) after adjustment for risk factors, CRP, FDP, and HSP70.  Addition of suPAR to 
the 3-BRS significantly improved the C-statistic, IDI and NRI for the primary outcome. A BRS of 
1, 2, 3 or 4 was associated with a 1.81, 2.59, 6.17, and 8.80-fold increase respectively in the risk 
of death and MI. The 4-BRS was also associated with severity of coronary artery disease and 
composite endpoints. 
Conclusion: SuPAR is independently predictive of adverse outcomes, and its addition to a 3-BRS 
comprised of CRP, FDP and HSP-70 improved risk reclassification. The clinical utility of 
employing a 4-BRS for risk prediction and management of patients with coronary artery disease 
warrants further study.   
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Introduction 
Coronary artery disease (CAD) continues to be the leading cause of mortality worldwide.1 The 
mechanisms involved in the development of atherosclerosis and subsequent plaque rupture 
that precipitate acute coronary events and death are complex and involve several pathways 
including key contributions of inflammation, immune dysregulation, stress, and thrombosis.2 
Clinical tools such as the Framingham risk score predict long-term risk of outcomes in the 
healthy population,3, 4 but fail to reliably prognosticate risk of adverse outcomes in patients 
with established CAD.5  
We recently identified a simple non-invasive risk score based on the concept that the greater 
the number of pathways related to plaque rupture that are activated in a given patient, the 
greater the risk of actual plaque rupture.6  This aggregate biomarker strategy for risk prediction 
was tested using the biomarkers C-reactive protein (CRP), representing inflammation, fibrin 
degradation products (FDP), representing the coagulation pathway, and heat shock protein-70 
(HSP-70) representing cell stress. The biomarker risk score (BRS) strategy was highly successful 
in predicting risk of near-term MI and death in patients with suspected or established CAD.6   
Soluble urokinase plasminogen activator receptor (suPAR) is a marker of immune activation and 
inflammation that appears to orchestrate cellular adhesion, migration, and proliferation during 
development of the atherosclerotic plaque.7 Higher circulating levels of suPAR are associated 
with incident cardiovascular disease (CVD) in the healthy population8‘9, and we and others have 
found that it also predicts incident CVD events and chronic kidney disease in subjects with 
CAD.10-12  
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The purpose of the present investigation is to determine (1) whether suPAR levels are 
associated with outcomes independent of the aforementioned markers of inflammation (CRP), 
hypercoagulable state (FDP) and cellular stress (HSP70), and (2) whether addition of suPAR to 
the 3-BRS improves prediction of future adverse events. 
Methods  
Study Population:   
Subjects were recruited as a part of the Emory Cardiovascular Biobank and consisted of 3278 
patients undergoing left heart catheterization for diagnosis of suspected CAD in Emory 
Healthcare hospitals between 2003 and 2009. Subjects with heart transplantation, severe 
valvular heart disease, congenital heart disease, severe anemia, recent blood transfusion, 
myocarditis, active inflammatory diseases, and cancer were excluded. Demographics, medical, 
smoking status, and risk factor prevalence were documented as previously described.6 Smoking 
was classified as non-smoker or current smoker. Subjects were noted to have hypertension or 
dyslipidemia if they had a documented history or were on treatment. Acute MI at enrollment 
was defined using universal criteria.13 Briefly, myocardial infarction was diagnosed with 
detection of a rise of cardiac troponin with either ischemic symptoms, dynamic EKG changes, or 
identification of an intracoronary thrombus by angiography. The study was approved by the 
Emory University Institutional Review Board. All subjects provided written informed consent. 
Outcomes and Follow-up: 
To minimize physician-imposed bias, we selected a composite endpoint consisting of hard 
outcomes of ischemic heart disease including all-cause death and non-fatal myocardial 
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infarction. Follow-up was conducted between 1 and 5 years for determination of the primary 
composite endpoint of all cause death and non-fatal MI, and the secondary endpoints of 
cardiovascular death, all cause death/MI/revascularization, and all cause death/MI/stroke.  
Follow-up data were collected by personnel blinded to the biomarker data through telephone 
interview, chart review and query of the Social Security Death Index and State records.  Two 
independent cardiologists, both blinded to the clinical and biomarker data, adjudicated the 
cause of death. Cardiovascular death was defined as death attributable to an ischemic 
cardiovascular cause (i.e. fatal MI, stroke, or peripheral arterial disease) or sudden death due to 
an unknown but presumed cardiovascular cause in high-risk patients. Medical records were 
accessed to validate all self-reported events including MI.13 
Identification of CAD and Severity Scoring: 
Luminal narrowing of coronary arteries were quantified using a modified AHA/ACC classification 
of the coronaries.14 Patients were classified as having non-significant CAD (visible plaque 
resulting in <50% luminal stenosis) or significant CAD (at least one major epicardial vessel with ≥ 
50% stenosis). Normal coronaries were defined as those with no visual stenosis of major 
epicardial arteries and smooth appearance during angiography and without history of prior 
coronary artery bypass graft (CABG) surgery or angioplasty. Quantitative angiographic scoring 
was performed using the Gensini score that quantifies CAD severity by a nonlinear points 
system for degree of luminal narrowing and has been shown to have prognostic significance.14, 
15 
Sample Collection:  
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Fasting arterial blood samples for serum and plasma were drawn before angiography and 
stored at -80º C (mean, 4.9 years). Details of the biomarker assays have been previously 
described. 6, 11 Briefly, serum CRP and FDP measurements were determined using a sandwich 
immunoassay by FirstMark, Inc., San Diego, CA. Serum HSP-70 was measured with a sandwich 
enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, Minnesota) and optimized by 
FirstMark. Plasma suPAR levels were measured using commercially available kits (suPARnostic 
kit, Virogates, Copenhagen, Denmark).  Minimum detectable CRP, FDP, HSP-70, and suPAR were 
0.1 mg/L, 0.06 μg/ml, 0.313 ng/ml, and 0.1 ng/mL, respectively.  
Statistical Analyses:  
Continuous variables are presented as mean (± SD) or median (IQR) and categorical variables as 
proportions (%). The student’s t-test and Chi-Square tests were used when appropriate. Mann-
Whitney U or Kruskall Wallis non-parametric tests were performed on non-normally distributed 
variables. The relationship between biomarkers and outcomes was determined using the Cox 
proportional-hazards regression in unadjusted models and in models adjusted for established 
risk factors that include clinically relevant covariates for CVD outcomes (age, gender, race, 
history of hypertension, diabetes, dyslipidemia, previous MI, acute MI at presentation, 
estimated glomerular filtration rate (eGFR), Gensini score, body mass index (BMI), left 
ventricular ejection fraction (LVEF), history of CABG, smoking status, and the use of aspirin, 
clopidogrel, and statins). Fine and Gray’s sub-distribution hazard model was used to analyze 
cardiovascular death outcome, considering non-cardiovascular death as the competing risk 
event.   
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The best discriminatory cutoff for each biomarker in association with the death/MI outcome 
was determined using the Youden’s index (sensitivity – (1-specificity)) from the Receiver 
Operating Characteristic (ROC) analysis to identify “high” vs. “low” levels. The Youden index is a 
global measure of a biomarker’s effectiveness that calculates to the maximum difference 
between sensitivity and 1-specificity.16 Cut points for CRP, FDP, HSP-70, and suPAR were 3 
mg/L, 1.0 μg/ml, 0.313 ng/ml, and 3.5 ng/ml, respectively, as described previously.6, 11 A 3-BRS 
was derived by counting the number of biomarkers above respective cut-points.  
Discrimination analysis for the prediction of each endpoint was calculated as the difference in 
C-statistic comparing the baseline model incorporating traditional risk factors (model 1), a 
second model including the 3 biomarkers (model 2), and lastly a model containing the 3 
biomarkers in addition to suPAR levels (model 3). C-statistics, continuous net reclassification 
index (NRI) and integrated discrimination improvement (IDI) metrics comparing model 3 to 
models 1 and 2 were calculated using the R package survC1 and survIDINRI.17-20  
Average annual event rates for each outcome measure were calculated by dividing the 
observed number of events by the observed event-specific number of person-years of follow-
up. Interaction terms of each covariate on the association of the aggregate BRS and the primary 
end point were evaluated and demonstrated using a forest plot.21 The independent association 
of the BRS with the presence of ≥50% stenosis in any major coronary artery was evaluated with 
a binary logistic regression model adjusting for known cardiovascular risk factors including age, 
gender, diabetes, hypertension, dyslipidemia, and smoking status. P values <0.05 from two-
sided tests were considered statistically significant. Statistical analyses were performed with 
SAS (Version 9.3; SAS Institute, NC, USA).   
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Results 
Relationship between biomarker risk score and clinical risk factors:  
The relationships between the categories of the BRS and the clinical and demographic 
factors are listed in Table#1. Although the absolute differences in most of the parameters were 
small, subjects with a higher BRS were more likely to be older, female, African American, 
diabetic, hypertensive, active smoker, and to have lower LVEF and lower eGFR. There was no 
significant difference in management strategy (i.e. medical vs. revascularization) between 
patients in different categories of the BRS.  
Relationship of biomarker risk score with angiographic CAD:  
Patients with higher BRS were more likely to have at least one epicardial vessel with ≥50% 
stenosis and higher burden of CAD as quantified by higher Gensini Score, Table#1. Conversely, 
visually normal coronary arteries were more likely to be present in those with a lower 
compared to a higher BRS. Compared to those with a BRS of 0 or 1, those with BRS ≥ 2 had 25% 
increased odds of having significant CAD (> 50% stenosis) (OR=1.25, p=0.013) independent of 
age, gender, diabetes, hypertension, dyslipidemia, and smoking status. Similarly, the BRS was 
an independent correlate of severity of CAD assessed by the Gensini score after adjustment for 
variables listed above.  
Clinical and demographic predictors of incident adverse outcomes: 
Over a median follow-up of 2.3 years and a total of 7539 patient years of follow-up, 269 
subjects died (8.2%), 116 had an MI (3.5%), 153 (4.7%) had cardiovascular death, 35 had stroke 
(1.1%), and 353 underwent revascularization (10.8%), Table#1. In a Cox proportional hazard 
Biomarker Risk Score Manuscript/R4/11.08.16 
 
10 
 
model for the composite endpoint of all cause death/MI adjusting for all the aforementioned 
demographic and clinical covariates, significant predictors were: age (years, HR: 1.02, 95% CI: 
1.01-1.03)), eGFR (ml/min, HR: 0.99, 95% CI: 0.993-0.999), acute MI (HR: 1.97, 95% CI: 1.49-
2.59), diabetes (HR: 1.65, 95% CI: 1.32-2.08), active smoking (HR: 1.42, 95% CI: 1.05-1.93), LVEF 
(%, HR: 0.98, 95% CI: 0.97-0.98), Gensini score (HR: 1.003, 95% CI: 1.001-1.005), aspirin use 
(HR=0.69, 95% CI: 0.46-0.85), and clopidogrel use (HR: 1.43, 95% CI: 1.11-1.84); p-value for all < 
0.05. We believe that the elevated hazard associated with clopidogrel use is likely related to a 
high risk inherent to individuals taking this antiplatelet medication.  
Relationship between biomarker risk score and outcomes:  
Correlation analyses between the 4 biomarkers revealed weak but significant correlations, 
Table#2. An increased (above cutoff) level of each biomarker was independently associated 
with future risk of all cause death, cardiovascular death, composite of death and MI, combined 
death, MI, and revascularization, and composite of death, MI, and stroke after adjustment for 
the noted clinical covariates. Only elevated CRP was not significantly associated with future 
cardiovascular death, Table#3. Importantly, a high suPAR level was an independent predictor of 
all incident outcome measures in models adjusted for all aforementioned variables as well as a 
3-BRS comprising of CRP, FDP, and HSP-70. For instance, a high suPAR level was independently 
associated with incident all-cause death/MI (HR=1.83, p<0.001), Table#3.  
The four-BRS was associated with a graded increase in risk of each of the endpoints noted. 
When analyzed as a numeric scale in Cox proportional hazard models adjusting for all previously 
described variables, each 1 unit increase in the BRS was associated with 1.94-fold increased risk 
of all-cause death, 1.71-fold increased risk of cardiovascular death, 1.77-fold increased risk of 
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death/MI, 1.45-fold increase in the risk of death/MI/revascularization, and 1.72-fold increased 
risk of death/MI/stroke (p<0.001 for all). Comparison of hazard ratios for those with 1, 2, 3, and 
4 elevated biomarkers compared to those with no elevated biomarker are presented in 
Table#3, and cumulative incidence plots in Figure#1. Thus, compared to those with a BRS of 0, 
those with a BRS of 4 had an 8.8-fold (p<0.001) increased odds of having death or MI, or a 6.76-
fold (p<0.001) increased risk of cardiovascular death. Average annual event rates increased in a 
graded fashion across the categories of the BRS with the 2.6% of subjects with a BRS of 4 having 
on average 21% per year risk of death/MI compared to a 1.1% event rate in the 28% of subjects 
with a BRS of 0, Figure#2. Average annual event rates for each endpoint across categories of the 
BRS are presented in Figure#2.  
Discrimination Testing:   
The addition of suPAR to a model consisting of clinical covariates and the 3-BRS was associated 
with significant improvement in risk reclassification metrics and c-statistic with respect to the 
primary endpoint of all-cause death and MI, as well as the outcomes of all-cause death, 
cardiovascular death and the combined outcomes Table#4.  
Discussion 
Several pathways are involved and act synergistically in the development of atherosclerotic 
plaque and its progression to the stage of plaque instability and rupture. We had previously 
identified a BRS comprised of CRP, FDP, and HSP-70 that predicted risk of incident MI and death 
but did not correlate with presence or severity of CAD.6 The present study demonstrates that 
the circulating level of suPAR is an independent predictor of adverse CVD outcomes after 
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adjustment for all traditional cardiovascular risk factors and levels of CRP, FDP and HSP70.  
Moreover, the addition of suPAR to a 3-BRS based on the aforementioned biomarkers improves 
risk reclassification metrics of the C-statistic, NRI, and IDI. When comparing this 4-BRS strategy 
to our prior study involving 3 biomarkers, we found that only the 4-BRS and not the 3-BRS was 
independently associated with both presence and severity of CAD.  
The Urokinase Plasminogen Activator (uPA) is a serine protease produced by smooth muscle 
cells, vascular endothelial cells, macrophages, monocytes and fibroblasts, and when bound to 
its receptor (uPAR), leads to the generation of plasmin.7, 22 uPAR is involved in several functions 
including migration, adhesion, fibrinolysis, and cell proliferation.23-25 Plasma suPAR reflects 
cellular shedding of uPAR, which is induced during inflammation; shedding appears to be free of 
circadian changes and is relatively stable during periods of acute stress.9, 26 suPAR has been 
reported to predict incident CVD independent of the Framingham risk score in healthy 
populations free of CVD27, 28 and in those with CVD. 10, 11   
CRP has been widely studied in populations free of CVD29, 30 as well as cohorts with established 
CAD; it predicts incident CVD and MACE independent of traditional cardiovascular risk factors.31, 
32 Heat shock proteins are abundant intracellular proteins that aid in a cell’s response to acute 
stress and are involved in protein folding and transport.33  HSP-70 is one of the more 
extensively studied HSPs, yet its relationship with CAD has been quite controversial.34 It appears 
that while lower levels are associated with long-term development of atherosclerotic plaque,34 
higher levels predispose to higher risk of plaque rupture and incident future outcomes.6 Fibrin 
degradation products are measures of ongoing fibrin/fibrinogen degradation. Increased plasma 
FDP level predicts incident cardiovascular events in patients with peripheral vascular disease.35 
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Plasma D-dimer, which is one of the products included in the FDP analysis, is a marker of 
turnover of cross-linked fibrin; it was higher in those with CAD compared to healthy controls36 
and predicted adverse cardiovascular events in healthy individuals independent of 
cardiovascular risk factors.37 Similarly, in the Bypass Angioplasty Revascularization Investigation 
2 Diabetes (BARI 2D) study, the diabetics with CAD had higher D-dimer levels that were 
associated with an increased risk of cardiac events. 38 FDP ELISA assay used in this study detects 
the full complement of FDP components, including D-dimer as well as fragments D and E and 
any additional intermediate products from fibrin degradation. 
Previous studies investigating the role of multiple biomarkers in populations without CVD have 
demonstrated only slight improvements in predictive potential (using C-statistic) when added to 
standard clinical models.39-41  In contrast, our study establishes the value of a multi-marker 
aggregate score in a high risk population with suspected or established CAD, a group in which 
traditional risk scores such as Framingham have failed to identify risk of recurrent CVD events. 
We have shown that despite a statistically significant two-by-two correlation between the four 
biomarkers, the observed correlation coefficients were rather modest. This finding is 
compatible with the concept that these biomarkers act independently and do so with their 
predominant activities involving separate biological pathways. It is well known that the immune 
system, partly due to stimulation of inflammatory pathways, plays an important role in the 
pathogenesis of atherosclerosis and in the activation of pathways leading to plaque rupture.42  
Here we have shown that a BRS comprised of suPAR (a biomarker of immune system activation 
and of inflammation) in addition to CRP, FDP, and HSP-70 significantly predicts all major 
outcomes as well as the severity of CAD.  Thus, whereas the HR for increase in risk of death and 
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MI was 5-fold greater in those who had 3 positive biomarkers compared to those with a BRS of 
0 using the risk score described previously, the HR was 8.8-fold greater in those with 4 positive 
biomarkers using the 4 aggregate BRS.6 This corresponds to an average annual event rate of 
21% in these patients. Use of this BRS in conjunction with other readily available clinical factors 
could potentially guide clinicians in appropriate identification of patients at highest risk with use 
of more aggressive treatment options, risk factor control, and behavioral modification 
counseling. Conversely, identification of patients at very low risk could prevent unnecessary 
testing in this population. Further studies are needed to evaluate the effect of the use of this 
BRS on tailoring of medical therapy.  
Strengths and Limitations:   
Our study has several strengths.  We enrolled individuals of both genders and races, those with 
acute MI, and patients with a range of LVEF, reflecting a population that is high risk yet typical 
of those undergoing cardiac catheterization. Biomarker evaluation was performed at one time 
point by the same lab personnel, which minimized variability.  C-statistic, NRI and IDI were 
calculated using survival models, which allows for better model discrimination and overall 
predictive ability. Limitations of our study include a one-time measurement of biomarkers that 
may not reflect fluctuations in their levels over time.  Despite rigorous attempts in controlling 
for confounding variables, our inability to adjust for a well-validated comorbidity index in this 
study further adds to limitations. Our results need to be further validated and should not be 
generalized to a population without suspected or known CAD. Furthermore, future studies are 
needed to assess cost-effectiveness of using this multi-marker BRS in routine clinical practice.  
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In conclusion, a 4-BRS representing inflammation, coagulation, cell stress, and immune 
pathways significantly predicts risk of MI and death, and significantly improves risk 
reclassification above and beyond a 3-BRS. Whether more aggressive medical management in 
individuals with high BRS would lead to a decrease in the BRS, and whether such a decrease, if it 
occurs, modifies subsequent risk of outcomes, remains to be studied.  
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Table 1. Baseline Characteristics 
  Total Number of elevated biomarkers 
    0 1 2 3 4   
Baseline Characteristics N=3278 N=923 N=1141 N=796 N=332 N=86 
P value 
for 
Trend 
Demographics        
Age (years) 63±12 62±11 62±13 64±12 66±11 66±11 <0.001 
Male Gender, N (%) 2105 (64%) 686 (74%) 740 (65%) 437 (55%) 189 (57%) 53 (62%) <0.001 
Caucasian, N (%) 2709 (83%) 793 (86%) 939 (82%) 647 (81%) 264 (79%) 66 (78%) 0.015 
Systolic BP (mmHg) 137±23 136±20 137±23 138±23 138±26 132±24 0.062 
Diastolic BP (mmHg) 76±12 76±11 76±12 75±12 75±13 74±11 0.045 
BMI (kg/m2) 30±6 29±5 30±6 30±7 30±7 28±6 <0.001 
Comorbidities        
Acute MI on presentation, N (%) 389 (11%) 57 (6.3%) 141 (12.5%) 110 (14%) 60 (18%) 1 (1.2%) <0.001 
History of prior MI, N (%) 981 (31%)  251 (28%) 319 (29%) 259 (33%) 124 (38%) 28 (34%) 0.001 
Diabetes, N (%) 1033 (31%) 199 (22%) 329 (29%) 316 (40%) 146 (44%) 43 (50%) <0.001 
Hypertension, N (%) 2362 (72%) 632 (68%) 818 (72%) 597 (75%) 255 (77%) 60 (70%) 0.010 
Dyslipidemia, N (%) 2291 (70%) 660 (71%) 805 (71%) 550 (69%) 229 (69%) 47 (55%) 0.024 
Current Smoking, N (%) 484 (15%) 90 (10%) 191 (17%) 143 (18%) 53 (17%) 7 (8.4%) <0.001 
History of prior CABG, N (%) 721 (22%) 192 (21%) 233 (20%) 169 (21%) 96 (29%) 31 (36%) <0.001 
History of prior Angioplasty, N (%) 1342 (42%) 382 (42%) 462 (41%) 328 (42%) 137 (42%) 33 (39%) 0.963 
LVEF (%) 53±12 55±11 54±12 52±14 50±14 44±18 <0.001 
Medications        
Statin use, N (%) 2378 (72%) 696 (75%) 831 (73%) 568 (71%) 231 (70%) 52 (60%) 0.016 
Aspirin use, N (%) 2652 (81%) 749 (81%) 931 (82%) 637 (80%) 272 (82%) 63 (73%) 0.371 
Clopidogrel use, N (%) 1516 (46%) 412 (45%) 532 (47%) 353 (44%) 183 (55%) 36 (42%) 0.010 
Beta Blocker use, N (%) 2075 (63%) 523 (57%) 720 (63%) 538 (68%) 235 (71%) 59 (69%) <0.001 
ACE-inh/ARB use, N (%) 2042 (62%) 536 (58%) 748 (67%) 504 (63%) 208 (63%) 46 (53%) 0.004 
Angiographic findings        
Gensini Angiographic Score [median (IQR)] 12 (0-50) 11 (0-50) 11 (0-48) 12 (0-48) 20 (2.1-61) 20 (1.4-85) 0.001 
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≥50% epicardial vessel stenosis, N (%) 2026 (66%) 547 (63%) 706 (66%) 494 (68%) 225 (73%) 54 (68%) 0.024 
Visually normal coronaries, N (%) 656 (20%) 208 (22.5%) 240 (21%) 155 (19%) 44 (13%) 9 (11%) 0.001 
Laboratory values        
GFR (ml/min) 76±47 81±44 82±49 71±49 60±44 54±43 <0.001 
LDL (mg/dl) 99±37 98±35 102±39 100±38 96±39 97±35 0.070 
HDL (mg/dl) 42±13 43±12 42±13 41±12 40±13 42±15 0.002 
Biomarkers        
CRP (mg/l) [median (IQR)] 3.0 (1.2-7.6) 1.1 (0.6-1.9) 3.4 (1.45-6.9) 6.0 (3.2-10) 9.6 (4.7-18) 8.9 (4.9-22) <0.001 
HSP-70 (ng/ml) [median (IQR)] 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-8.0) 4.0 (0.0-189.2) 264 (106-635) <0.001 
FDP (µg/ml) [median (IQR)] 0.5 (0.3-0.8) 0.4 (0.3-0.5) 0.5 (0.3-0.7) 0.6 (0.4-1.0) 1.2 (0.7-2.1) 1.7 (1.2-4.6) <0.001 
suPAR (ng/ml) [median (IQR)] 3.0 (2.3-3.9) 2.4 (2.0-2.9) 2.8 (2.2-3.4) 3.9 (3.0-4.9) 4.5 (3.7-6.0) 5.3 (4.1-7.1) <0.001 
Management Strategy       0.539 
Medical Management, N (%) 1863 (57%) 551 (60%) 632 (55%) 443 (56%) 188 (57%) 49 (57%) -- 
Revascularization, N (%) 1260 (38%) 337 (36%) 449 (39.4%) 316 (40%) 127 (38.3%) 31 (36%) -- 
Other, N (%) 155 (4.7%) 35 (3.8%) 60 (5.3%) 37 (4.6%) 17 (5.1%) 6 (7%) -- 
Follow-up Events        
MI, N (%) 116 (3%) 16 (2%) 40 (3%) 25 (3%) 29 (9%) 6 (7%) <0.001 
All-cause death, N (%) 269 (8%) 21 (2%) 46 (4%) 79 (10%) 86 (26%) 37 (43%) <0.001 
Cardiovascular death, N (%) 153 (5%) 14 (1%) 27 (2%) 43 (5%) 48 (14%) 21 (24%) <0.001 
All-cause death/MI, N (%) 363 (11%) 34 (4%) 82 (7%) 98 (12%) 109 (33%) 40 (46%) <0.001 
All-cause death/MI/revascularization, N (%) 628 (19%) 92 (10%) 187 (16%) 167 (21%) 138 (42%) 44 (51%) <0.001 
All-cause death/MI/stroke, N (%) 392 (12%) 39 (4%) 91 (8%) 108 (14%) 113 (34%) 41 (48%) <0.001 
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Table 2.  Associations between biomarkers 
 HSP-70 
 
FDP CRP 
suPAR 
r* 
p 
 
0.16 
<0.001 
0.27 
<0.001 
 
0.27 
<0.001 
CRP 
r 
p 
 
0.072 
<0.001 
 
0.22 
<0.001 
 
FDP 
r 
p 
 
0.18 
<0.001 
 
  
*R value represents correlation coefficient of the Spearman bivariate correlation test. 
Statistically significant direct two-by-two correlations were observed between biomarkers. 
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Table 3. Association between major cardiovascular events and the biomarkers individually and as the BRS. 
 
All-Cause Death Cardiovascular Death* All-Cause Death and MI All-Cause Death, MI, 
Revascularization 
All-Cause Death, MI, Stroke 
HR (95% CI); p-value HR (95% CI); p-value HR (95% CI); p-value HR (95% CI); p-value HR (95% CI); p-value 
All biomarkers in same model 
CRP ≥3.0 mg/L 1.69 (1.26-2.27), p<0.001 1.57 (0.39-6.38), p=0.53 1.58 (1.24-2.02), p<0.001 1.31 (1.09-1.56), p=0.003 1.58 (1.25-2.00), p<0.001 
HSP70 > 0.313ng/mL 1.98 (1.46-2.67), p<0.001 1.79 (1.17-2.73), p=0.01 2.22 (1.71-2.87), p<0.001 1.94 (1.60-2.35), p<0.001 1.99 (1.56-2.55), p<0.001 
FDP ≥ 1.0 ug/mL 1.87 (1.42-2.46), p<0.001 1.79 (1.25-2.58), p=0.002 1.57 (1.23-1.99), p<0.001 1.41 (1.16-1.70), p<0.001 1.60 (1.27-2.01), p<0.001 
suPAR ≥ 3.5 ng/ml 2.31 (1.71-3.13), p<0.001 2.12 (1.37-3.26), p<0.001 1.83 (1.43-2.35), p<0.001 1.29 (1.07-1.55), p=0.006 1.78 (1.40-2.25), p<0.001 
Categorical 
1 vs 0 markers 1.68 (0.96-2.93), p=0.065 1.59 (0.79-3.19), p=0.20 1.81 (1.19-2.76), p=0.005 1.63 (1.25-2.11), p<0.001 1.74 (1.18-2.59), p=0.005 
2 vs 0 markers* 3.40 (2.0-5.76), p<0.001 2.52 (1.27-5.01), p=0.01 2.59 (1.70-3.94). p<0.001 1.93 (1.47-2.54), p<0.001 2.49 (1.68-3.69), p<0.001 
3 vs 0 markers* 7.59 (4.46-12.91), p<0.001 5.60 (2.72-11.56), p<0.001 6.17 (4.05-9.40), p<0.001 3.68 (2.75-4.91), p<0.001 5.60 (3.76-8.34), p<0.001 
4 vs 0 markers* 11.87 (6.5-21.65), p<0.001 6.76 (2.81-16.26), p<0.001 8.8 (5.32-14.57), p<0.001 4.17 (2.82-6.17), p<0.001 7.99 (4.93-12.93), p<0.001 
      
Analyses were adjusted for age, gender, race, body mass index, glomerular filtration rate, acute myocardial infarction, history of previous myocardial infarction, hypertension, 
dyslipidemia, diabetes, left ventricular ejection fraction, history of coronary bypass graft surgery, history of coronary angioplasty, active smoking, Gensini angiographic severity score, 
aspirin use, Statin use, and Clopidogrel use.  *Fine and Gray’s sub-distribution hazard model was used to analyze cardiovascular death outcome, considering non-cardiovascular death 
as the competing risk event. Since no patients with 0 elevated markers experienced cardiovascular death in the data, patients with 0 or 1 elevated marker was treated as the reference 
category for the analysis of cardiovascular death.       
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Table 4. Discrimination analysis of the biomarker risk score with major cardiovascular events. 
Model C-statistic (95% CI) ΔC-Statistic (95%CI) Continuous  NRI (95% CI) Relative IDI (95% CI) 
 All-cause Death/MI 
3 Biomarker Risk Score 0.71 (0.67-0.75) - - - 
3 Biomarker Risk Score + suPAR 0.74 (0.70-0.78) 0.03 (0.01, 0.05) 0.60 (0.28-0.96) 0.10 (0.03-0.17) 
 All-cause Death 
3 Biomarker Risk Score 0.71 (0.67-0.75) - - - 
3 Biomarker Risk Score + suPAR 0.74 (0.70-0.78) 0.03 (0.01,0.06) 0.61 (0.27-0.99) 0.11 (0.03-0.19) 
 Cardiovascular Death 
3 Biomarker Risk Score 0.71 (0.66-0.76) - - - 
3 Biomarker Risk Score + suPAR 0.73 (0.68-0.79) 0.02 (0.00-0.05) 0.60 (0.13-0.86) 0.08 (0.01-0.16) 
 All-Cause Death/MI/Revascularization 
3 Biomarker Risk Score 0.66 (0.63-0.69) - - - 
3 Biomarker Risk Score + suPAR 0.67 (0.64-0.70) 0.01 (0.00-0.02) 0.57 (0.26-0.83) 0.05 (0.01-0.09) 
 All-Cause Death/MI/Stroke 
3 Biomarker Risk Score 0.70 (0.66-0.75) - - - 
3 Biomarker Risk Score + suPAR 0.73 (0.70-0.77) 0.03 (0.01-0.05) 0.60 (0.10-0.99) 0.10 (0.02-0.16) 
 
  
*Baseline model comprised of age, gender, race, body mass index, a history of smoking, glomerular filtration rate, history of myocardial infarction,  history of 
revascularization (coronary bypass graft or percutaneous coronary intervention), hypertension, dyslipidemia, diabetes, left ventricular ejection fraction, presence of 
obstructive coronary artery disease, aspirin use, statin use, and clopidogrel use.   
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Figure Legends: 
 
Figure 1. Cumulative incidence plots for all-cause death (A), cardiovascular death (B), and all-cause death/MI (C) per category of the 
biomarker risk score.  
Figure 2. Annual event rates of major cardiovascular events in each category of the biomarker risk score. Percent of patients within 
each biomarker risk category is listed beside each score.  
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Figure 1 
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